Skip to content
Trioxsalen
Trisoralen (trioxsalen) is a small molecule pharmaceutical. Trioxsalen was first approved as Trisoralen on 1982-01-01. It is used to treat albinism, psoriasis, and vitiligo in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
hereditary congenital and neonatal diseases and abnormalitiesD009358
skin and connective tissue diseasesD017437
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Trioxsalen
Tradename
Company
Number
Date
Products
TRISORALENBausch Health CompaniesN-012697 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
albinism—D000417E70.3
psoriasisEFO_0000676D011565L40
vitiligoEFO_0004208D014820L80
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D05: Antipsoriatics
— D05A: Antipsoriatics for topical use
— D05AD: Psoralens for topical use
— D05AD01: Trioxysalen
— D05B: Antipsoriatics for systemic use
— D05BA: Psoralens for systemic use
— D05BA01: Trioxysalen
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DementiaD003704F03——1——1
Psychophysiologic disordersD011602F45.9——1——1
SchizophreniaD012559EFO_0000692F20——1——1
DepressionD003863F33.9——1——1
Anxiety disordersD001008EFO_0006788F41.1——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTRIOXSALEN
INNtrioxysalen
Description
Trioxsalen is 7H-Furo[3,2-g]chromen-7-one in which positions 2, 5, and 9 are substituted by methyl groups. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered orally in conjunction with UV-A for phototherapy treatment of vitiligo. After photoactivation it creates interstrand cross-links in DNA, inhibiting DNA synthesis and cell division, and can lead to cell injury; recovery from the cell injury may be followed by increased melanisation of the epidermis. It has a role as a photosensitizing agent and a dermatologic drug.
Classification
Small molecule
Drug classanti-inflammatory agents (salicylic acid derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1
Identifiers
PDB—
CAS-ID3902-71-4
RxCUI10844
ChEMBL IDCHEMBL1475
ChEBI ID28329
PubChem CID5585
DrugBankDB04571
UNII IDY6UY8OV51T (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 325 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
820 adverse events reported
View more details